Comparative PK? [Study Per­for­mance]

posted by PVRC – India, 2021-05-12 17:48 (1052 d 00:13 ago) – Posting: # 22346
Views: 1,919

Hi Helmut,

Thank you for the reply..,

❝ ❝ […] the agency …


❝ May I ask: Which agency?


The FDA

❝ … recommend to demonstrate comparative PK in the absence of bioequivalence.


❝ Do I get you right: The study was planned to demonstrate BE, failed, and now you were asked about ‘comparative PK’? I never came across such a term.


The following is the guidance....

To use pharmacokinetics (PK) bridging only, you should establish bioequivalence between test drug the listed drug under both fasting and fed conditions.

If the bioequivalence cannot be established due to different food effect or other reasons, you should demonstrate comparable PK and pharmacodynamics (PD) between Test and reference.

To establish "comparable PK" between test and reference, the active drug exposure (AUC, Cmax and Ctrough) of test at the proposed dosing regimen should be comparable with the listed drug.

Thanks

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
100 visitors (0 registered, 100 guests [including 13 identified bots]).
Forum time: 17:02 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5